



**DOCKET NO.: CELL-0289/P0164-USW01 PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Stephen Martin Courtney, et al.

Confirmation No.: 8405

**Application No.: 10/523,118** 

**Group Art Unit: 1614** 

Filing Date: October 4, 2005

Examiner: Not Yet Assigned

FURANTHIAZOLE DERIVATIVES AS HEPARANASE INHIBITORS

DATE OF DEPOSIT: May 19, 2006

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

TYPED NAME: Jane E. Inglese REGISTRATION NO.: 48,444

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

 $\boxtimes$ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

## DOCKET NO.: CELL-0289/P0164-USW01 PATENT

	the ab	ove identified application as set forth in § 1.491, before the mailing date					
	of a f	irst Office Action on the merits of the above-identified application, or					
	before the mailing date of a first Office Action after the filing of request for						
	continued examination under § 1.114, no additional fee is required.						
	In acc	ordance with § 1.97(c), this Information Disclosure Statement is being					
	filed after the period set forth in § 1.97(b) above but before the mailing date of						
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or						
	before	an action that otherwise closes prosecution in the application, therefore:					
		Certification in Accordance with § 1.97(e) is attached; or					
		The fee of $$180.00$ as set forth in § 1.17(p) is attached.					
	In acc	ordance with § 1.97(d), this Information Disclosure Statement is being					
	filed a	ofter the mailing date of either a Final Action under § 1.113 or a Notice					
	of All	owance under § 1.311 but before, or simultaneously with, the payment					
	of the	Issue Fee, therefore included are: Certification in Accordance with §					
	1.97(e	); and the submission fee of \$180.00 as set forth in § 1.17(p).					
$\boxtimes$	Copie	s of reference numbers 1 - 16 listed on the attached Form PTO-1449 are					
	enclos	ed herewith.					
	Copie	s of reference numbers - on the attached Form PTO 1449					
	are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).						
		Copies of references - are not being submitted because					
		they were previously cited by or submitted to the U.S. Patent and					
	Trademark Office in patent application number , filed f which a claim for priority under 35 U.S.C. § 120 has been made in the						
		instant application.					

## DOCKET NO.: CELL-0289/P0164-USW01 PATENT

- 3 -

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-

3050. This form is submitted in duplicate.

Date: May 19, 2006

Jane E. Inglese

Registration No. 48,444

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2006 WW



8	heparanase activity," Cancer Res., 1999, 59, 3433-3441  8 Sarodnick, G., et al., "Heterocyclic substituted thiazoles as thiabendazole analogues, Z. Chem., 1979, 19(1), 21-22 (German, no English abstract available)										
7	tumor growth and metastasis using novel <i>in vitro</i> assays for angiogenesis and heparanase activity," <i>Cancer Res.</i> , <b>1999</b> , <i>59</i> , 3433-3441										
6	113-116, Accession No. Kempter, G., et al., "Mel	substituted arabinofuranosylpyrimiding nucleosides," J. Med. Chem., 1977, 20(1), 113-116, Accession No. 833809, 1 page  Kempter, G., et al., "Mehrfach heterocyclish substutuierte thiazole," Z. Chem., 1970,									
5	heparinomimetic mannopentaose phosphate sulfate (PI-88)," Clin. Appl. Thromb. Hemost., 2001, 7(2), 131-140  Folkman, J., et al., "control of angiogenesis by heparin and other sulfated polysaccharides," Adv. Exp. Med. Biol., 1992, 313, 355-364										
3											
2	extracellular matrix and is released by heparitinase and heparin-like molecules,"  Biochemistry, 1989, 28, 1737-1743  CAS Registry No. 338786-69-9, XP-002259645, 2003, 1 page										
· · · · · · · · · · · · · · · · · · ·	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  1 Bashkin, P., et al., "Basic fibroblast growth factor binds to subendothelial										
OTHE	D DOCUMENTS (In all a	Confirmation No. 8405	Double and Dones Etc.								
	nent of Commerce Trademark Office	Filing Date October 4, 2005	Group 1614								
Cited 1	nt and Publications by Applicant sheets if necessary)	Applicant Stephen Martin Courtney, et al.									
	-1449 Modified	Docket No. CELL-0289/ P0164-USw01	Application No. 10/523,118								

EXAMINER				DATE CONSIDERED			
	16	0 218 147	07/03/24	GB			
	15	199 55 803	05/23/01	DE		X abstract	
	14	WO 2004/013132 A1	02/12/04	PCT			,
	13	WO 01/35967 A1	05/25/01	PCT		X abstract	
Initial		Document No.	Date	Country		YES	NO
Examiner	1	FORE	IONIAII	ATT DOCUMENTS		Tro	nslation
	L	FODE	ICN PATE	ENT DOCUMENTS			<u></u>
Initial		No.	Date	Name		Class	Subclass
Examiner	1	Document	, I AI EN	BOCONIENTS			
		TT (	DATENT	8405  T DOCUMENTS			· · · · · · · · · · · · · · · · · · ·
				Confirmation No.			
		rtment of Commerce d Trademark Office	<b>;</b>	Filing Date October 4, 2005	Group 1614		
	Cite	d by Applicant al sheets if necessary		Applicant Stephen Martin Courtney, et al.			
		ent and Publications		CELL-0289/ P0164-USw01	10/523,118		
For	m PT	O-1449 Modified	1	Docket No. CELL 0280/ Application No.			